New! Sign up for our free email newsletter.
Science News
from research organizations

A universal coronavirus vaccine could save billions of dollars if ready before next pandemic, study suggests

Date:
January 11, 2024
Source:
CUNY Graduate School of Public Health and Health Policy
Summary:
A new study suggests that once developed, a universal vaccine in advance of the next coronavirus epidemic/pandemic can save up to 7 million hospitalizations and 2 million deaths even when it is the only intervention being implemented and its efficacy is as low as 10 percent.
Share:
FULL STORY

What if scientists had developed a universal coronavirus vaccine in the years prior to 2020 so that it was available at the start of the COVID-19 pandemic? A universal coronavirus vaccine targets parts of the virus that are common to either many or all coronaviruses, thereby offering some degree of protection against a range of strains. A new study suggests if such a vaccine were available at the start of the pandemic, it could have saved millions of lives, prevented suffering, and saved billions of dollars in direct medical and other costs until the strain-specific (i.e., SARS-CoV-2) vaccine went through the entire development, testing, and emergency use authorization process that lasted 10 months.

In the study, researchers from the Public Health Informatics, Computational and Operations Research (PHICOR) group, the CUNY Graduate School of Public Health and Health Policy (CUNY SPH), and the National School of Tropical Medicine at Baylor College of Medicine (BCM) show that having a universal vaccine at the start of the pandemic would have had substantial health and economic benefits under almost all scenarios tested. The study will be published Jan. 11 in the Lancet's eClinicalMedicine.

In order to determine the value of investing in developing and stockpiling a universal coronavirus vaccine, the team developed a computational model that simulated the entire U.S. population, the introduction and spread of a novel coronavirus like SARS-CoV-2 in 2020 and the resulting health (e.g., infections, hospitalizations) and economic (e.g., direct medical costs, productivity losses) outcomes. The experiments simulated what would happen if a universal coronavirus vaccine was available at the start of the COVID-19 pandemic.

Vaccinating with a universal coronavirus vaccine as a standalone intervention (e.g., no face mask use or social distancing) was cost-saving even when its efficacy was as low as 10% and only 10% of the U.S. population received the vaccine. For example, when a universal coronavirus vaccine has 10% efficacy, vaccinating a quarter of the U.S. population within two months of the start of the pandemic averts an average of 14.6 million infections and saves over $27 billion in direct medical costs. Such low vaccine coverage at the start of the pandemic could occur if a vaccine were only made available to certain high-risk subpopulations (e.g., 65 years and older, those with weakened immune systems, frontline workers), similar to the approach when mRNA vaccines became available in December 2020.

"COVID-19 was the third major and serious coronavirus epidemic or pandemic following SARS in 2002 and MERS in 2012, thus, we should anticipate a fourth coronavirus outbreak within the next decade or so," says Peter J. Hotez, MD, PhD, dean of Baylor's National School of Tropical Medicine and co-director of the Texas Children's Hospital Center for Vaccine Development. "A universal vaccine is cost-effective and cost-saving and a priority for advancement."

A universal coronavirus vaccine was also shown to be highly cost-effective even if a more specific and more efficacious vaccine came to market. For example, the study shows if it takes four months or longer for a strain-specific vaccine to reach the market, using a universal vaccine was still cost cost-saving. In a scenario where a strain-specific vaccine has 90% efficacy but is unavailable for two months after the start of the pandemic, the results from the model show that vaccinating only 10% of the population with a universal vaccine that has 10% efficacy at the start of the pandemic can save over $2 billion in societal costs (e.g., direct medical costs and productivity losses from absenteeism). Given the time required to develop a strain-specific vaccine during a pandemic to match circulating strains of the virus, this highlights the importance of having a universal vaccine readily available as a stopgap.

"Our study shows the importance of giving as many people as possible in a population at least some degree of immune protection as soon as possible," explains Bruce Y. Lee, MD, MBA, executive director of PHICOR and professor at CUNY SPH. "Having a universal vaccine developed, stockpiled, and ready to go in the event of a pandemic could be a game-changer even if a more specific vaccine could be developed three to four months later."

Generally, results from the model found that a universal vaccine would end up saving money if the cost to get a person vaccinated (e.g., cost of the vaccine itself, distribution, administration, storage, research, and development) is as high as $10,390 from a societal perspective.

This work was supported by the National Science Foundation proposal number 2054858, the Agency for Healthcare Research and Quality (AHRQ) via grant 1R01HS028165-01, the National Institute of General Medical Sciences as part of the Models of Infectious Disease Agent Study network under grants R01GM127512 and 3R01GM127512-01A1S1, the National Center for Advancing Translational Sciences of the National Institutes of Health via award number U54TR004279, the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number P01AI172725, and by the City University of New York (CUNY) in support of the Pandemic Response Institute (PRI). Statements in the manuscript do not necessarily represent the official views of, or imply endorsement by, the National Institute of Health, AHRQ, the US Department of Health and Human Services, CUNY, or the PRI.


Story Source:

Materials provided by CUNY Graduate School of Public Health and Health Policy. Note: Content may be edited for style and length.


Journal Reference:

  1. Sarah M. Bartsch, Kelly J. O'Shea, Danielle C. John, Ulrich Strych, Maria Elena Bottazzi, Marie F. Martinez, Allan Ciciriello, Kevin L. Chin, Colleen Weatherwax, Kavya Velmurugan, Jessie Heneghan, Sheryl A. Scannell, Peter J. Hotez, Bruce Y. Lee. The potential epidemiologic, clinical, and economic value of a universal coronavirus vaccine: a modelling study. eClinicalMedicine, 2024; 102369 DOI: 10.1016/j.eclinm.2023.102369

Cite This Page:

CUNY Graduate School of Public Health and Health Policy. "A universal coronavirus vaccine could save billions of dollars if ready before next pandemic, study suggests." ScienceDaily. ScienceDaily, 11 January 2024. <www.sciencedaily.com/releases/2024/01/240111112246.htm>.
CUNY Graduate School of Public Health and Health Policy. (2024, January 11). A universal coronavirus vaccine could save billions of dollars if ready before next pandemic, study suggests. ScienceDaily. Retrieved February 28, 2024 from www.sciencedaily.com/releases/2024/01/240111112246.htm
CUNY Graduate School of Public Health and Health Policy. "A universal coronavirus vaccine could save billions of dollars if ready before next pandemic, study suggests." ScienceDaily. www.sciencedaily.com/releases/2024/01/240111112246.htm (accessed February 28, 2024).

Explore More
from ScienceDaily

RELATED STORIES